Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2009
    The Therapeutic Role of CMA-MEF2D in the Survival of DA Neurons

    Objective/Rationale:
    Parkinson’s Disease is caused by the death of a particular group of dopaminergic (DA) neurons in the brain. Our recent studies revealed that a nuclear protein named MEF2D is...

  • Target Validation, 2009
    SHP-2 Phosphatase: A New Pharmacological Target for Parkinson's Disease?

    Objective/Rationale:
    Levodopa, the most effective therapy for Parkinson’s disease, induces severe involuntary movements termed dyskinesias. The development of these motor dysfunctions has been...

  • Target Validation, 2009
    Validation of Nurr1 as a Drug Target for the Treatment of PD

    Objective/Rationale:
    Pharmacological methods to prevent or delay the degeneration of dopaminergic neurons in Parkinson’s disease (PD) are not available. We propose that Nurr1, a protein found in these...

  • Target Validation, 2009
    Validation of Cyclophilin D, a Protein Involved in the Mitochondrial Permeability Transition, as a Target for Parkinson's Disease Therapy

    Objective/Rationale:
    Mitochondria dysfunction has long been proposed to contribute to the pathogenesis of Parkinson’s Disease. In addition to their role in ATP production, mitochondria play an...

  • Therapeutics Development Initiative, 2009
    Dose-Response Assessment of ReS9-S7, a First-in-Class, Disease-modifying Drug Candidate for Treatment of Parkinson's Disease

    Objective/Rationale:
    ReS9-S7, a novel disease-modifying drug candidate directed against alpha-synuclein instigated neuronal toxicity, is planned to enter clinical Phase I studies in 2009/2010...

  • Therapeutics Development Initiative, 2009
    Effect of Novel Neuronal Nicotinic Receptor Compounds on Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease

    Objective/Rationale:
    The idea that compounds targeting neuronal nicotinic receptors may be useful for the treatment of L-dopa-induced abnormal involuntary movements (AIMs), or dyskinesias, stemmed from...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.